Getagraph.com logo
S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

Sanntidsoppdatering for Ocugen Inc [OCGN]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
BUY
100.00%
return 9.47%
SELL
100.00%
return -10.94%
Sist oppdatert3 mai 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

0.76% $ 1.330

KJøP 115766 min ago

@ $0.657

Utstedt: 14 feb 2024 @ 21:30

Avkastning: 102.59%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 6.16 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Profile picture for Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...

Stats
Dagens volum 4.73M
Gjennomsnittsvolum 9.74M
Markedsverdi 342.25M
EPS $-0.0300 ( 2024-05-03 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.12
ATR14 $0.00700 (0.53%)
Insider Trading
Date Person Action Amount type
2024-04-16 Qamar Huma Buy 308 465 Option (Right to Buy)
2024-03-18 Qamar Huma Sell 0 Common Stock
2023-09-15 Breininger Michael Buy 0
2024-01-03 Musunuri Shankar Sell 180 204 Common Stock
2024-01-03 Upadhyay Arun Sell 41 633 Common Stock
INSIDER POWER
65.36
Last 96 transactions
Buy: 10 862 012 | Sell: 2 992 475

Volum Korrelasjon

Lang: -0.40 (neutral)
Kort: -0.76 (moderate negative)
Signal:(36.122) Neutral

Ocugen Inc Korrelasjon

10 Mest positive korrelasjoner
EQRR0.944
PVAL0.943
RNA0.942
THRN0.938
RAIL0.936
DVLU0.935
PCAR0.934
SG0.934
SHLD0.933
LFMDP0.932
10 Mest negative korrelasjoner
RMRM-0.938
RGC-0.934
UONEK-0.926
TCPC-0.922
VORB-0.921
TSP-0.919
BRQS-0.918
HCDIP-0.916
AGRX-0.91
QNRX-0.909

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ocugen Inc Korrelasjon - Valuta/Råvare

The country flag -0.38
( neutral )
The country flag -0.13
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.25
( neutral )

Ocugen Inc Økonomi

Annual 2023
Omsetning: $6.04M
Bruttogevinst: $5.33M (88.34 %)
EPS: $-0.260
FY 2023
Omsetning: $6.04M
Bruttogevinst: $5.33M (88.34 %)
EPS: $-0.260
FY 2022
Omsetning: $0
Bruttogevinst: $-1.07M (0.00 %)
EPS: $-0.360
FY 2021
Omsetning: $0.00
Bruttogevinst: $0.00 (0.00 %)
EPS: $-0.300

Financial Reports:

No articles found.

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.